Yükleniyor... / Loading...
This study aimed to evaluate the accuracy of molecular diagnostic technologies in patients diagnosed with lung adenocarcinoma (a type of non-small cell lung cancer). It enrolled patients aged 18 and older who had not yet received lung cancer treatment and could provide a tissue sample. It was conducted as a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Female or male, 18 years of age or older. * Patients with histologically or cytological proven diagnosis of NSCLC, pathologically identified as adenocarcinoma. * Patient naïve in lung cancer treatment * Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the study prior to enrollment. * Patients must give consent to the research use of their archived or tumor FFPE tissue, and if available, 2 blood tubes. Exclusion Criteria: * Prior chemotherapy treatment.